Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-10-09
2000-09-19
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514408, 514386, 514410, 514416, 514533, 514642, 514659, A61K 3114, A61K 3140, A61K 31403, A61K 314188, A61K 31445
Patent
active
06121289&
ABSTRACT:
This invention provides methods of treatment of addiction to tobacco comprising intranasal administration of nicotinic antagonists.
REFERENCES:
patent: 2831027 (1958-04-01), Pfister, III et al.
patent: 3025294 (1962-03-01), Huebner
patent: 3717650 (1973-02-01), Herr et al.
patent: 3731683 (1973-05-01), Zaffaroni
patent: 3884976 (1975-05-01), Bernauer et al.
patent: 3979494 (1976-09-01), Zaffaroni
patent: 4336243 (1982-06-01), Sanvordeker et al.
patent: 4846199 (1989-07-01), Rose
patent: 4891380 (1990-01-01), Williams et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5272168 (1993-12-01), Imperato et al.
patent: 5316759 (1994-05-01), Rose et al.
patent: 5519044 (1996-05-01), Imperato et al.
patent: 5554610 (1996-09-01), Williams et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5624898 (1997-04-01), Frey, II
patent: 5691365 (1997-11-01), Crooks et al.
patent: 5703101 (1997-12-01), Rose et al.
patent: 5726190 (1998-03-01), Rose et al.
patent: 5732717 (1998-03-01), Watanabe et al.
patent: 5760049 (1998-06-01), Viner
Rose, "Nicotine Addiction and Treatment", Annu. Rev. Med. 47:493-507 (1996).
Paul Clarke, "Nicotine Dependence--Mechanisms and Therapeutic Strategies", Biochem. Soc. Symp. 59:83-95 (1993).
Jed Rose, Ph.D. et al., "Mecamylamine Combined With Nicotine Skin Patch Facilitates Smoking Cessation Beyond Nicotine Patch Treatment Alone", Clinical Pharmacology & Therapeutics, No. 1, 56:86-99 (1994).
Elan Corporation News Room, "Elan Reports on Nicotine Patch Studies and Its Late Stage Development Pipeline Status", Dublin Ireland, Nov. 24, 1998 (2 pages).
Toshiyasu Sakane et al., "Transport of Cephalexin to the Cerebrospinal Fluids directly From the Nasal Cavity", J. Pharm. Pharmacol. 43:449-451 (1991).
Forest S. Tennant, Jr., et al., "Clinical Evaluation of Mecamylamine for Withdrawal From Nicotine Dependence" NIDA Research Monograph Series 49 "Problem of Drug Dependence 1983" Editor: Louis S. Harris, Ph.D., Mar. 1984 pp. 239-246.
Forest S. Tennant, Jr., et al., "Withdrawal from Nocotine Dependence Using Mecamylamine: Comparison of Three-Week and Six-Week Dosage Schedules", Research Monograph Series 55 "Problem of Drug Dependence 1984" Editor: Louis S. Harris, Ph.D., Mar. 1984 pp. 291-297.
David H. Malin et al., "Nicotiine Abstinence Syndrome Precipitated by the Competitive Nicotinic Antagonist Dihydro-.beta.-Erythroidine", Pharmacology Biochemistry and Behavior, No. 3, 60:609-613 (1998).
B.E. Hildebrand et al., "Behavioral Manifestations of the Nicotine Abstinence Syndrome in the Rat: Peripheral Versus Central Mechanisms", Psychopharmacology 129:348-356 (1997).
J. Prignot, "Pharmacological Approach to Smoking Cessation", Eur Respir J 2:550-560 (1989).
Kenneth S.E. Su et al., "Nasal Drug Delivery System of a Quaternary Ammonium Compound: Clofilium Tosylate", Journal of Pharmaceutical Sciences No. 9, 73:1251-1254 (1984).
H. El-Bizri et al., "Blockade of Nicotinic Receptor-Mediated Release of Dopamine From Striatal Synaptosomes by Chlorisondamine Administered in vivo", Br. J. Pharmacol. 111:414-418 (1994).
B.S. Clarke, "Chronic Central Nicotinic Blockade After a Single Administration of the Bisquaternary Ganglion-Blocking Drug Chlorisondamine", Br. J. Pharmac. 83:527-535 (1984).
B.S. Clarke et al., "Characterization of the Locomotor Stimulant Action of Nicotine in Tolerant Rates", Br. J. Pharmac. 80:587-594 (1983).
I.P. Stolerman, "Could Nicotine Antagonists be used in Smoking Cessation?", British Journal of Addition 81:(81)47-53 (1986).
J.E. Henningfield et al., "Stimulus Properties of nicotine in Animals and Human Volunteers: A Review", Behavioral Pharmacology: The Current Status pp. 443-449 (1984).
I.P. Stolerman, "Psychopharmacology of Nicotine: Stimulus Effects and Receptor Mechanisms" Handbook of Psychopharmacology, 19:421-465 (1975).
Spivack Phyllis G.
Theramax Inc.
LandOfFree
Method for enhanced brain delivery of nicotinic antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for enhanced brain delivery of nicotinic antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for enhanced brain delivery of nicotinic antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073593